Healthcare
Live Price
Offline$216.49
-2.14% today
1Y Change
+16.83%
Window
Jun 20, 2025 → Jun 18, 2026
Coverage: 250 bars · Jun 20, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
AbbVie Inc. (ABBV) is a Healthcare stock with a market cap of $368.20B and listed on NYSE. The stock last traded around $216.49 and up 16.8% across the available one-year price window (Jun 20, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of +8.6%, EPS growth of -1.2%, a dividend yield of 3.2%. What stands out right now is revenue +8.6%, EPS -1.2%, free cash flow -0.1% with operating margin 27.6% and ROIC 10.6%. The dividend matters to the case here, with a current yield around 3.2%. Valuation already assumes a fairly strong business story at P/E 101.5 and price/sales 5.9. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines ABBV price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
ABBV
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
ABBV Max Drawdown
-19.23%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for ABBV and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$56.2B
-3.2% YoY
FY Net Income
$11.5B
-2.5% YoY
Free Cash Flow
$22.0B
-9.3% YoY
Revenue Growth
+8.6%
EPS Growth
-1.2%
Gross Margin
73.5%
Net Margin
5.8%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 61.2B | 56.3B | 54.3B | 58.1B | 56.2B |
| Gross Profit | 51.2B | 39.4B | 33.9B | 40.6B | 38.8B |
| Operating Income | 21.2B | 9.1B | 12.8B | 18.1B | 17.9B |
| EBITDA | 28.3B | 14.9B | 17.2B | 24.2B | 23.9B |
| Net Income | 4.2B | 4.3B | 4.9B | 11.8B | 11.5B |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 5.2B | 5.5B | 12.8B | 9.2B | 9.7B |
| Total Assets | 134.0B | 135.2B | 134.7B | 138.8B | 146.5B |
| Total Liabilities | 137.2B | 131.8B | 124.3B | 121.5B | 131.1B |
| Shareholder Equity | -3.3B | 3.3B | 10.4B | 17.3B | 15.4B |
| Total Debt | 69.1B | 67.8B | 60.1B | 64.2B | 77.6B |
| Net Debt | 63.8B | 62.3B | 47.3B | 55.0B | 67.8B |
Cash flow positioning
Latest Full Year
Operating Cash Flow
22.8B
-8.7% YoY
Capital Expenditures
787M
-13.2% YoY
Free Cash Flow
22.0B
-9.3% YoY
Key ratios
Gross Margin
73.5%
Operating Margin
27.6%
Net Margin
5.8%
ROE
-311.4%
Debt / Equity
-21.06x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.